Hormone replacement therapy contraindications after menopause should be checked before dose, brand, or route. Hormone replacement therapy can be helpful. It can also be the wrong tool.
The 2022 Menopause Society hormone-therapy statement frames systemic hormone replacement therapy as an individualized decision. Timing, route, dose, symptom severity, uterus status, and personal risk all matter. For women younger than 60 or within 10 years of menopause onset who have no contraindications, Menopause Society says the benefit-risk ratio is favorable for bothersome vasomotor symptoms and prevention of bone loss. For initiation after 60 or more than 10 years from menopause onset, the benefit-risk ratio is less favorable because absolute risks are higher. [1]
That is why a good hormone replacement therapy visit starts with contraindications, not with a dose.
Who should avoid systemic HRT after menopause?
Unexplained vaginal bleeding needs evaluation before hormone decisions. A history of estrogen-sensitive cancer, blood clots, stroke, heart attack, or active liver disease can also change the risk-benefit balance.
These are not small details. A current DailyMed label for estradiol and norethindrone acetate lists contraindications that include undiagnosed abnormal genital bleeding, breast cancer or history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism or history of those conditions, active arterial thromboembolic disease such as stroke or heart attack or history of those conditions, hepatic impairment or disease, and known protein C, protein S, antithrombin deficiency, or other thrombophilic disorders. [2]
The Women's Health Initiative estrogen-plus-progestin trial enrolled 16,608 postmenopausal women ages 50 to 79 with an intact uterus and tested conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day versus placebo. After a mean 5.2 years, the trial stopped early because the global risk-benefit index supported risks exceeding benefits. [3]
The estimated Women's Health Initiative hazard ratios were 1.29 for coronary heart disease, 1.26 for invasive breast cancer, 1.41 for stroke, and 2.13 for pulmonary embolism. Absolute excess risks per 10,000 person-years were 7 more coronary heart disease events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers. Absolute reductions were 6 fewer colorectal cancers and 5 fewer hip fractures per 10,000 person-years. [3]
That trial does not answer every modern hormone replacement therapy question. It does show why a personal risk review matters.
Evidence limits: contraindication lists are a screen, not a full decision
The evidence is limited when one Women's Health Initiative result, one label list, or one route claim is used as the whole hormone replacement therapy answer. Women's Health Initiative tested a specific estrogen-plus-progestin regimen in a broad postmenopausal population, while current practice still has to account for age, timing, route, dose, uterus status, symptom target, and contraindications. [1] [2] [3]
That does not weaken the warning. It makes the warning more useful: first decide whether systemic hormone replacement therapy is appropriate at all, then discuss route, dose, monitoring, and nonhormonal or local options when systemic estrogen is not a fit.
Estrogen and progestin plans are prescription hormone therapy. A clinician should decide whether either one fits the risk profile.
Route helps only after eligibility
Transdermal estrogen is often discussed because American College of Obstetricians and Gynecologists reviewed route-related clot-risk differences. American College of Obstetricians and Gynecologists notes that orally administered estrogen may have a prothrombotic effect, while transdermal estrogen has little or no effect on some prothrombotic substances, and that clinicians should consider possible thrombosis-sparing properties of transdermal estrogen during shared decision-making. [4]
A review of oral versus transdermal estrogen and venous thrombosis summarized five observational studies and reported pooled venous thromboembolism risk ratios of 1.9 for oral estrogen users and 1.0 for transdermal estrogen users. [5]
But route is not a free pass. A patch, gel, spray, or pill still needs clinician review when there is bleeding, cancer history, clot history, stroke history, liver disease, or complex cardiovascular risk.
A safer clinical sequence is: first eligibility, then route, then dose, then monitoring.
If HRT is not a fit, the symptom still deserves care
Women do not usually search this topic because they want abstract risk language. They search because symptoms are real and they need to know whether hormone replacement therapy is a reasonable option for them. The screening step works best when it feels useful, not punitive.
If systemic hormone replacement therapy is not a fit, the next path may still include care: local vaginal therapy for genitourinary syndrome of menopause, fezolinetant or other nonhormonal options for hot flashes, sleep-specific evaluation, or cardiometabolic risk work that makes future decisions clearer.
That distinction matters. A contraindication to systemic estrogen does not automatically mean every menopause symptom must be endured, and a lower-risk profile does not mean hormones should start without goals, monitoring, and stopping rules.
The 2023 Menopause Society nonhormone statement lists evidence-supported nonhormonal vasomotor options, including cognitive behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant, and oxybutynin, depending on evidence level and fit. [6]
A structured hormone assessment should separate the symptom target before choosing a route: hot flashes, sleep, genitourinary syndrome of menopause, bleeding, mood, bone prevention, or another issue.
Screening table: what can change the HRT answer?
| Signal | Why it matters | Practical routing |
|---|---|---|
| Unexplained bleeding after menopause | Bleeding needs evaluation before systemic hormone decisions. | Evaluate bleeding first, especially if persistent or recurrent. |
| Breast cancer or estrogen-sensitive cancer history | Systemic hormone exposure may be inappropriate or require oncology input. | Specialist discussion or nonhormonal/local alternatives may come first. |
| Prior deep vein thrombosis, pulmonary embolism, stroke, or heart attack | Label contraindications and baseline vascular risk matter. [2] | Do not assume route or dose can solve eligibility. |
| Active liver disease or hepatic impairment | Systemic hormone metabolism and label contraindications matter. [2] | Review liver history and alternatives. |
| Known thrombophilic disorder | Protein C, protein S, antithrombin deficiency, and other thrombophilias are listed contraindications. [2] | Avoid routine systemic hormone replacement therapy decisions without specialist-level risk review. |
| Age over 60 or more than 10 years since menopause onset | Menopause Society describes a less favorable benefit-risk ratio because absolute risks rise. [1] | Reassess indication, route, dose, and nonhormonal options. |
| Uterus present | Unopposed systemic estrogen raises endometrial concerns. [2] | Progestogen/endometrial protection strategy matters if systemic estrogen is used. |
Decision table: who may fit and who should avoid systemic HRT
| Decision point | More likely to fit | Avoid or slow down |
|---|---|---|
| Main symptom | Moderate to severe hot flashes, night sweats, or genitourinary syndrome of menopause symptoms with clear goals. | General wellness, anti-aging, weight loss, or mood optimization without a symptom target. |
| Timing | Under 60 or within 10 years of menopause onset and no contraindications. [1] | Starting after 60 or more than 10 years from menopause without a strong indication. |
| Cancer and bleeding history | No unexplained bleeding and no estrogen-sensitive cancer history. | Unexplained bleeding, breast cancer history, or estrogen-dependent neoplasia. [2] |
| Vascular history | No prior deep vein thrombosis/pulmonary embolism, stroke, heart attack, or known thrombophilia. | Prior clot, stroke, heart attack, thrombophilia, or complex uncontrolled risk. [2] |
| Route discussion | Route is chosen after eligibility and risk review. | "Patch is always safe" or "bioidentical is automatically safer" framing. |
| If systemic hormone replacement therapy is not a fit | Local genitourinary syndrome of menopause care or nonhormonal vasomotor symptoms options are considered. | Symptoms are dismissed because systemic estrogen is not appropriate. |
Red flags after starting or while considering HRT
Red flags include postmenopausal bleeding, new breast mass or concerning breast symptoms, chest pain, sudden shortness of breath, one-sided leg swelling or pain, sudden neurologic symptoms, severe new headache, vision loss, jaundice, or signs of allergic reaction. These need urgent or prompt evaluation rather than dose adjustment at home.
Less urgent but important review points include new migraine pattern, rising blood pressure, new gallbladder symptoms, worsening triglycerides, medication interactions, new smoking status, or a change in cancer, clot, or liver history.
What to ask a clinician
Ask:
- Do I have any absolute or relative contraindication to systemic hormone replacement therapy?
- Does my age or time since menopause change the benefit-risk balance?
- Would local vaginal therapy treat my symptom with less systemic exposure?
- Would a nonhormonal option fit better for hot flashes, sleep, or mood symptoms?
- What warning symptoms should prompt urgent care after starting therapy?
- If I have a uterus, what protects the endometrium if systemic estrogen is used?
- What is the stop or reassessment rule if benefits do not outweigh side effects?
Bottom line
A midlife woman should not be told to "just optimize hormones."
The safer question is: "Do my symptoms, history, and risks make systemic hormone replacement therapy reasonable, or should I consider local or nonhormonal options first?"
Menopause Society also has a nonhormone therapy statement for vasomotor symptoms, which matters when systemic hormone replacement therapy is not a good fit. [6]
How the assessment helps
A structured assessment can organize symptom target, age, time since menopause, uterus status, bleeding, breast cancer history, clot or stroke history, liver disease, thrombophilia, blood pressure, medicines, and urgent symptoms so a clinician can decide whether systemic hormone replacement therapy, local therapy, or a nonhormonal option fits. It is not a hormone replacement therapy eligibility decision by itself.
Related reading:
- Hormone Therapy After Menopause: Benefits and Risks.
- Bleeding on hormone replacement therapy After Menopause.
- Bone Density After Menopause.
- Clonidine for Hot Flashes After Menopause.
References
[1] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[2] DailyMed. Estradiol and norethindrone acetate tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c786d6-91bd-4eea-9455-ff2abc08372f
[3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi:10.1001/jama.288.3.321 https://pubmed.ncbi.nlm.nih.gov/12117397/
[4] ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121(4):887-890. doi:10.1097/01.aog.0000428645.90795.d9 https://pubmed.ncbi.nlm.nih.gov/23635705/
[5] Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457-63. doi:10.1097/moh.0b013e32833c07bc https://pubmed.ncbi.nlm.nih.gov/20601871/
[6] New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/gme.0000000000002200 https://pubmed.ncbi.nlm.nih.gov/37252752/